Albacyte A1 cells, albacyte b cells, albacyte IGG sensitized cells, and albacyte antibody screen (3-cells)
Ended Awarded Last action
- Contract number
- HT940624F0146
- Awardee
-
Alba Bioscience, Inc. UEI V6KNKL6BDHL7
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $21,949
Award facts
- Opportunity
-
- HT940624Q0087 Solicitation number
- Contract value 40% obligated
-
- $32,923.80 Current, with exercised options
- $54,873.00 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Jacksonville, FL 32214, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Funding Only Action | $10,975 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $0 | |
| Other Administrative Action | $10,975 | |
| Original award | $0 |
About this award
The Defense Health Agency awarded a delivery order valued at $54,873 to Alba Bioscience, Inc. on October 1, 2024, for the supply of Albacyte A1 cells, B cells, IgG sensitized cells, and antibody screening products (3-cell configuration). Alba Bioscience, a Chicago-based subsidiary of Quotient Biodiagnostics, Inc., is a specialized provider of in vitro diagnostic products and blood banking materials to federal healthcare systems. This delivery order was issued without set-aside designation and is structured as a firm fixed-price contract with an ultimate completion date of September 3, 2029. The contract is fulfilled from Jacksonville, FL and represents part of Alba Bioscience's broader portfolio of immunohematology reagents essential for transfusion services and diagnostic testing.
This award builds on Alba Bioscience's established presence as a critical supplier within the federal healthcare marketplace, particularly for the Defense Logistics Agency and Department of Veterans Affairs. The company currently holds two significant Blanket Purchase Agreements serving as Indefinite Delivery Vehicles with the VA under GSA Schedule 65-VII for In Vitro Diagnostics, Reagents, and Tests, valued at approximately $199,672 and $218,841 respectively, enabling streamlined procurement of blood banking supplies across VA medical facilities nationwide. Alba Bioscience's competitive positioning in specialized blood typing and antibody identification products has resulted in sustained federal contracting activity without reliance on small business set-aside preferences, reflecting the proprietary nature of its diagnostic offerings.
Quick answers
Who was awarded contract HT940624F0146?
HT940624F0146 was awarded to Alba Bioscience, Inc. by Defense Health Agency (Department of Defense) on October 1, 2024.
How much is contract HT940624F0146 worth?
The government has obligated $21,949 on HT940624F0146. Its current value, with exercised options, is $32,924. Its potential value, with all options, is $54,873.
Is contract HT940624F0146 an order under another contract?
Yes. HT940624F0146 is a delivery order under 36F79721D0259, a federal supply schedule, on Invitro Diagnostics, Reagents, Test (FSS-65-VII).
Was contract HT940624F0146 competed?
The extent of competition for HT940624F0146 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award